Genzyme Drug Patent Portfolio
Genzyme owns 10 orange book drugs protected by 37 US patents with Cerezyme having the least patent protection, holding only 1 patent. And Cerdelga with maximum patent protection, holding 8 patents. Given below is the list of Genzyme's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11708370 | 20 Feb, 2041 | Active | |
| US12178818 | 13 Oct, 2040 | Active | |
| US10888544 | Methods for treating Gaucher disease | 13 Dec, 2038 | Active |
| US11091759 | Methods and compositions for treating a Serpinc1-associated disorder | 07 Dec, 2036 | Active |
| US8940744 | 06 Sep, 2033 | Active | |
| US9266895 | 06 Sep, 2033 | Active | |
| US9994576 | 06 Sep, 2033 | Active | |
| US9127274 | Serpinc1 iRNA compositions and methods of use thereof | 22 Mar, 2033 | Active |
| US9376680 | Serpinc1 iRNA compositions and methods of use thereof | 15 Mar, 2033 | Active |
| US9580427 | 01 Mar, 2033 | Active | |
| US12465586 | 05 Jun, 2032 | Active | |
| US10888547 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | 31 Jan, 2031 | Active |
| US9095509 | Sachet formulation for amine polymers | 06 Dec, 2030 | Active |
| US11458119 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | 24 Nov, 2030 | Active |
| US8067427 | Pharmaceutical compositions comprising ZD6474 | 08 Aug, 2028 | Active |
| US7196205 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | 26 Jun, 2026 | Active |
| US6987102 | Methods to mobilize progenitor/stem cells | 22 Jul, 2023 | Expired |
| US7897590 | Methods to mobilize progenitor/stem cells | 22 Jul, 2023 | Expired |
| US6916802 | Amino ceramide-like compounds and therapeutic methods of use | 29 Apr, 2022 | Expired |
| US7253185 | Amino ceramide-like compounds and therapeutic methods of use | 29 Apr, 2022 | Expired |
| US7615573 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | 29 Apr, 2022 | Expired |
| US8642608 | Quinazoline derivatives as VEGF inhibitors | 06 Feb, 2022 | Expired |
| US7173038 | Quinazoline derivatives as VEGF inhibitors | 14 Aug, 2021 | Expired |
| US6733780 | Direct compression polymer tablet core | 18 Oct, 2020 | Expired |
| USRE42152 | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity | 10 Dec, 2018 | Expired |
| US5661136 | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents | 14 Jul, 2018 | Expired |
| US5661136 | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents | 14 Jan, 2018 | Expired |
| USRE42353 | Quinazoline derivatives and pharmaceutical compositions containing them | 23 Sep, 2017 | Expired |
| US5840566 | Isolation of a gene encoding human thyrotropin beta subunit | 24 Nov, 2015 | Expired |
| US6365127 | Isolation of a gene encoding human thyrotropin beta subunit | 24 Nov, 2015 | Expired |
| US5667775 | Phosphate-binding polymers for oral administration | 16 Sep, 2014 | Expired |
| US5549892 | Enhanced in vivo uptake of glucocerebrosidase | 27 Aug, 2013 | Expired |
| US5496545 | Phosphate-binding polymers for oral administration | 11 Aug, 2013 | Expired |
| US6509013 | Method of making phosphate-binding polymers for oral administration | 11 Aug, 2013 | Expired |
| US7014846 | Phosphate-binding polymers for oral administration | 11 Aug, 2013 | Expired |
| US7459151 | Phosphate-binding polymers for oral administration | 11 Aug, 2013 | Expired |
| US6858203 | Method of making phosphate-binding polymers for oral administration | 11 Aug, 2013 | Expired |
Latest Legal Activities on Genzyme's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Genzyme.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jun, 2024 | US10888547 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jun, 2024 | US10888544 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 May, 2023 | US8067427 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Jan, 2023 | US9095509 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jan, 2023 | US7985418 |
|
Recordation of Patent Grant Mailed
Critical
| 04 Oct, 2022 | US11458119 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 04 Oct, 2022 | US11458119 |
|
Email Notification
Critical
| 15 Sep, 2022 | US11458119 |
|
Issue Notification Mailed
Critical
| 14 Sep, 2022 | US11458119 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Aug, 2022 | US7897590 (Litigated) |
|
Email Notification
Critical
| 29 Jul, 2022 | US11458119 |
| Mailing Corrected Notice of Allowability | 29 Jul, 2022 | US11458119 |
| Dispatch to FDC | 28 Jul, 2022 | US11458119 |
|
Application Is Considered Ready for Issue
Critical
| 28 Jul, 2022 | US11458119 |
| Corrected Notice of Allowability | 26 Jul, 2022 | US11458119 |
Genzyme's Drug Patent Litigations
Genzyme's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 03, 1996, against patent number US5840566. The petitioner , challenged the validity of this patent, with KOURIDES et al as the respondent. Click below to track the latest information on how companies are challenging Genzyme's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11458119 | November, 2020 |
Decision
(27 Sep, 2021)
| Hanlan Liu et al. | |
| US10888547 | April, 2019 |
Decision
(30 Apr, 2020)
| Genzyme Corporation | |
| US5840566 | January, 1996 |
Decision
(04 Jul, 1776)
| KOURIDES et al | |
Genzyme Drug Patents' Oppositions Filed in EPO
Genzyme drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 26, 2012, by Generics [Uk] Limited. This opposition was filed on patent number EP02750370A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16175117A | May, 2020 | Hetero Labs Limited | Granted and Under Opposition |
| EP16175117A | May, 2020 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP16175117A | May, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10184509A | May, 2020 | Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH | Granted and Under Opposition |
| EP10184509A | May, 2020 | Zentiva, k.s. | Granted and Under Opposition |
| EP10184509A | May, 2020 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP10184509A | May, 2020 | Sandoz AG | Granted and Under Opposition |
| EP10184509A | May, 2020 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP10184509A | May, 2020 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP10184509A | May, 2020 | Generics [UK] Limited (trading as Mylan) | Granted and Under Opposition |
| EP06824928A | Jul, 2016 | Alpex Pharma S.A. | Opposition rejected |
| EP10785289A | Feb, 2015 | SANDOZ AG | Patent maintained as amended |
| EP02750370A | Sep, 2012 | Actavis group PTC ehf | Revoked |
| EP02750370A | Sep, 2012 | Taylor Wessing LLP | Revoked |
| EP02750370A | Sep, 2012 | Generics [UK] Limited | Revoked |
Genzyme's Family Patents
Genzyme Drug List
Given below is the complete list of Genzyme's drugs and the patents protecting them.
1. Caprelsa
Caprelsa is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8067427 | Pharmaceutical compositions comprising ZD6474 |
08 Aug, 2028
(2 years from now)
| Active |
| US8642608 | Quinazoline derivatives as VEGF inhibitors |
06 Feb, 2022
(3 years ago)
| Expired |
| US7173038 | Quinazoline derivatives as VEGF inhibitors |
14 Aug, 2021
(4 years ago)
| Expired |
| USRE42353 | Quinazoline derivatives and pharmaceutical compositions containing them |
23 Sep, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caprelsa's drug page
2. Cerdelga
Cerdelga is protected by 8 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10888544 | Methods for treating Gaucher disease |
13 Dec, 2038
(12 years from now)
| Active |
| US12465586 |
05 Jun, 2032
(6 years from now)
| Active | |
| US10888547 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
31 Jan, 2031
(5 years from now)
| Active |
| US11458119 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
24 Nov, 2030
(4 years from now)
| Active |
| US7196205 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
26 Jun, 2026
(5 months from now)
| Active |
| US6916802 | Amino ceramide-like compounds and therapeutic methods of use |
29 Apr, 2022
(3 years ago)
| Expired |
| US7253185 | Amino ceramide-like compounds and therapeutic methods of use |
29 Apr, 2022
(3 years ago)
| Expired |
| US7615573 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
29 Apr, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cerdelga's drug page
3. Cerezyme
Cerezyme is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5549892 | Enhanced in vivo uptake of glucocerebrosidase |
27 Aug, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cerezyme's drug page
4. Clolar
Clolar is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5661136
(Pediatric)
| 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
14 Jul, 2018
(7 years ago)
| Expired |
| US5661136 | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
14 Jan, 2018
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clolar's drug page
5. Mozobil
Mozobil is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6987102 | Methods to mobilize progenitor/stem cells |
22 Jul, 2023
(2 years ago)
| Expired |
| US7897590 | Methods to mobilize progenitor/stem cells |
22 Jul, 2023
(2 years ago)
| Expired |
| USRE42152 | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
10 Dec, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mozobil's drug page
Explore Our Curated Drug Screens
6. Qfitlia
Qfitlia is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11091759 | Methods and compositions for treating a Serpinc1-associated disorder |
07 Dec, 2036
(10 years from now)
| Active |
| US9127274 | Serpinc1 iRNA compositions and methods of use thereof |
22 Mar, 2033
(7 years from now)
| Active |
| US9376680 | Serpinc1 iRNA compositions and methods of use thereof |
15 Mar, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qfitlia's drug page
7. Renagel
Renagel is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6733780 | Direct compression polymer tablet core |
18 Oct, 2020
(5 years ago)
| Expired |
| US5667775 | Phosphate-binding polymers for oral administration |
16 Sep, 2014
(11 years ago)
| Expired |
| US5496545 | Phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US6509013 | Method of making phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US7014846 | Phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US7459151 | Phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Renagel's drug page
8. Renvela
Renvela is protected by 7 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9095509 | Sachet formulation for amine polymers |
06 Dec, 2030
(4 years from now)
| Active |
| US5667775 | Phosphate-binding polymers for oral administration |
16 Sep, 2014
(11 years ago)
| Expired |
| US5496545 | Phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US6509013 | Method of making phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US6858203 | Method of making phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US7014846 | Phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US7459151 | Phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Renvela's drug page
9. Thyrogen
Thyrogen is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5840566 | Isolation of a gene encoding human thyrotropin beta subunit |
24 Nov, 2015
(10 years ago)
| Expired |
| US6365127 | Isolation of a gene encoding human thyrotropin beta subunit |
24 Nov, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Thyrogen's drug page
10. Wayrilz
Wayrilz is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11708370 |
20 Feb, 2041
(15 years from now)
| Active | |
| US12178818 |
13 Oct, 2040
(14 years from now)
| Active | |
| US8940744 |
06 Sep, 2033
(7 years from now)
| Active | |
| US9266895 |
06 Sep, 2033
(7 years from now)
| Active | |
| US9994576 |
06 Sep, 2033
(7 years from now)
| Active | |
| US9580427 |
01 Mar, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wayrilz's drug page